US 12,431,232 B2
Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods
Sarah Lomas, Cheshire (GB); Michael Barnish, Cheshire (GB); and Johnny Parvani, Phoenix, AZ (US)
Assigned to REVIV GLOBAL LTD, Knutsford (GB)
Filed by REVIV GLOBAL LTD, Knutsford (GB)
Filed on Dec. 20, 2023, as Appl. No. 18/391,300.
Application 18/391,300 is a division of application No. 17/880,920, filed on Aug. 4, 2022, granted, now 11,894,121.
Claims priority of provisional application 63/230,516, filed on Aug. 6, 2021.
Prior Publication US 2024/0120061 A1, Apr. 11, 2024
Int. Cl. G16H 20/17 (2018.01); G16H 10/60 (2018.01); G16H 50/70 (2018.01); G16H 70/40 (2018.01); G16H 70/60 (2018.01)
CPC G16H 20/17 (2018.01) [G16H 10/60 (2018.01); G16H 50/70 (2018.01); G16H 70/40 (2018.01); G16H 70/60 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A system for creating a genetically personalized intravenous or intramuscular nutrition therapy treatment formula, the system comprising:
a plurality of genetic testing kits, each testing kit configured to determine genetic information of one of a plurality of patients, the plurality of patients positioned geographically remotely from each other;
a plurality of electronic devices, each electronic device configured to receive the genetic information of one of the plurality of patients, medical information of the one of the plurality of patients, and therapeutic objectives of the one of the plurality of patients; and
a server comprising a database storing a personalized nutrition therapy formula creation algorithm, wherein the server is configured to wirelessly receive the genetic information, the medical information, and the therapeutic objectives of each of the plurality of patients,
wherein the server is configured to, for each of the plurality of patients:
output to the electronic device a custom intravenous or intramuscular nutrition therapy treatment formula for the patient from the personalized nutrition therapy formula creation algorithm based on the medical information, genetic information, and therapeutic objectives of the patient, wherein the ingredients of the custom intravenous or intramuscular nutrition therapy formula comprise one or more micronutrients identified by the personalized nutrition therapy formula creation algorithm as a match for the medical information, genetic information, and therapeutic objectives of the patient based on individual scores stored in the database of a plurality of existing individual scientific literature references relating to the one or more micronutrients and individual treatment scores stored in the database of previous intravenous or intramuscular nutrition therapy treatments comprising the one or more micronutrients, wherein the patient is treated with the custom intravenous or intramuscular nutrition therapy treatment formula;
receive feedback data about results of the custom intravenous or intramuscular nutrition therapy treatment formula after the patient has been treated based on the custom intravenous or intramuscular nutrition therapy treatment formula, wherein the feedback data comprises feedback about measured bloodwork, epigenetic changes, improvements or declines in symptoms, progress towards reaching therapeutic objectives, vital signs, overall health and fitness, or physical or mental energy;
create an individual treatment score based on the feedback data and store the individual treatment score in the database;
update the personalized nutrition therapy formula creation algorithm to incorporate the individual treatment score for subsequent patients; and
create future custom intravenous or intramuscular nutrition therapy treatment formulas based on the updated personalized nutrition therapy formula creation algorithm, wherein the updated personalized nutrition therapy formula creation algorithm is configured to create custom intravenous or intramuscular nutrition therapy treatment formulas comprising micronutrients that most closely match patient needs based on all available patient medical information, genetic information, and therapeutic objectives, and most current aggregated feedback based on real patients with similar genes and symptoms.